WAYNE, PA — Cagent Vascular, Inc. has announced the launch of its latest innovation, the Serranator SL-PRO™ PTA Serration Balloon Catheter, designed to address the challenges of treating tibial and pedal artery disease. This groundbreaking device combines advanced technology with enhanced design features to deliver targeted and effective vascular intervention.
The Serranator SL-PRO™ uses Cagent’s proprietary Serration Technology, which generates 1,000 times more point force than standard balloons, allowing for controlled and predictable arterial expansion with minimal dissection. The redesigned platform enhances deliverability and trackability, making it easier for physicians to treat conditions like challenging tibial disease and pedal interventions.
“As an experienced Serranator operator, my team has grown accustomed to the benefits of Serration, including great lumen gain, a low complication rate, and the significant reduction in vessel recoil,” said Dr. Michael Lichtenberg, Chief Medical Officer and Director of Angiology at Arnsberg Clinic in Germany. “The SL-PRO takes this further by offering a more deliverable platform while maintaining the benefits of this proven technology. It is particularly impactful for treating complex diseases in the pedal arteries.”
Cagent Vascular CEO Brian Walsh expressed his excitement over the product launch, stating, “We are committed to developing solutions that empower physicians in the fight against peripheral artery disease. With over 20,000 Serranation procedures completed and growing clinical data, the Serranator has established itself as a valuable tool. The SL-PRO expands our capabilities, allowing us to treat vascular diseases from hip to toe.”
The Serranator SL-PRO™ and its sister devices are FDA-cleared and utilize micro-serration technology to create linear, interrupted scoring along arterial surfaces, ensuring effective expansion even in challenging lesion morphologies. This “slow-and-low” inflation strategy enhances treatment precision and contributes to superior clinical outcomes.
With the launch of the Serranator SL-PRO™, Cagent Vascular continues its mission to advance the treatment of peripheral artery disease. By providing innovative tools that deliver safer and more effective outcomes, the company is poised to improve patient quality of life and push the boundaries of vascular intervention.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.